Clinical Pharmacology & Therapeutics

FIGURES AND TABLES

FROM:

Individual Genomes Instead of Race for Personalized Medicine

PC Ng, Q Zhao, S Levy, RL Strausberg and JC Venter

BACK TO ARTICLE
Figure 1 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Figure 1.

Four variants in CYP genes (CYP2C9*2, CYP2C9*3, CYP2C19*2, and CYP2C19*3) that show different allele frequencies among various ethnic groups. For each variant, its frequencies in the African-American (Af), Asian (As)/Chinese (Ch), and Caucasian (Ca) populations are shown. The nomenclature for a CYP variant is the gene name followed by the allele, which is indicated by an asterisk; for example, CYP2C9*2 is the *2 allele in the CYP2C9 gene. The frequencies for these variants and additional variants can be found in the article by Xie et al. 4

Full figure and legend (11K)
Figure 2 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Figure 2.

The genotypes of James Watson and J. Craig Venter in six major CYP genes involved in drug metabolism. This is not a comprehensive list; there are additional genes with genetic variants relevant to ADRs16 that are not shown here. Dr. Watson's genotypes were obtained from the CSHL website (http://jimwatsonsequence.cshl.edu) and Dr. Venter's from Levy et al. 8 Dr. Watson's sequence comes from the relatively recent 454 Life Sciences technology and may need further validation to assess accuracy. The CYP variants' effects and allele designations are from the Human Cytochrome P450 Allele Nomenclature Committee (http://www.cypalleles.ki.se). The wild-type allele for a CYP gene is designated *1A. The substrates for the CYP genes were taken from PharmGKB17 and are not complete lists. (Photographs from Wikimedia Commons (Watson) and Heather Kowalski (Venter).)

Full figure and legend (39K)
BACK TO ARTICLE